Primary Cervical Dystonia (Trihexyphenidyl)

PreclinicalSmall molecule

Primary Cervical Dystonia (Trihexyphenidyl) is one of 16 small molecule programs targeting Dystonia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DystoniaActive, not recruiting

DystoniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Dystonia

#DrugCompanyPhaseTrials

BOTULINUM TOXIN TYPE B

Eisai

Approved

1 2

Xeomin

MMerz Therapeutics GmbH

Approved

1 3

Dysport

Ipsen

Phase 3

1 4

Keppra

UCB

Phase 2

1 5

Austedo

Teva

Phase 2

1 6

Zonegran

Mylan Pharmaceuticals Inc

Phase 3

1 7

Neuronox

MMedy-Tox

Phase 3

2 8

Penbritin-S

Bristol-Myers Squibb

Phase 1

1 9

T2000

Sun Pharmaceutical Industries, Inc.

Phase 2

1 10

Incobotulinumtoxin a

UUniversity of Utah

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dystonia1 trial

Neuroimaging of Dystonia

Completed·UUniversity of Florida··NCT02046447·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Primary Cervical Dystonia (Trihexyphenidyl). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Primary Cervical Dystonia (Trihexyphenidyl) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Primary Cervical Dystonia (Trihexyphenidyl). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Florida

Primary Cervical Dystonia (Trihexyphenidyl)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dystonia1 trial

References

Drug Info

Quick Facts

Related News